3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
62
Other hematologic neoplasm
16
Plasma cell
4
Dermatologic
2
Sarcoma
1
Head & Neck
1
CNS
1
Conditions
Astrocytoma
5
Glioma
4
Glioblastoma
4
Oligodendroglioma
3
Neuroblastoma
3
Gliosarcoma
3
Central Nervous System Neoplasms
3
Optic Nerve Glioma
2
Brain Neoplasms
2
Stomach Neoplasms
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Neurofibromatosis 1
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Meningioma
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hematologic Neoplasms
1
Familial ependymoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Interventions
Filgrastim
11
Temozolomide
9
Melphalan
9
Cyclophosphamide
9
Radiotherapy
7
Busulfan
7
Magnetic Resonance Spectroscopy
6
Rituximab
5
Psychiatric Rehabilitation
5
Methotrexate
5
Etoposide
5
Cytarabine
5
Carboplatin
5
sargramostim
4
fludarabine
4
etoposide phosphate
4
Thiotepa
4
Nivolumab
4
Methylprednisolone
4
Flow Cytometry
4
Alemtuzumab
4
Vincristine
3
Topotecan
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Pemetrexed
3
Granulocyte Colony-Stimulating Factor
3
Early Intervention, Educational
3
Drug Therapy
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Lenalidomide
×
CNS
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled